Effect of Enteral Vitamin A on Fecal Calprotectin in Extremely Preterm Infants: A Nested Prospective Observational Study

Neonatology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Abhijeet A. Rakshasbhuvankar ◽  
J. Jane Pillow ◽  
Sanjay Keshav Patole ◽  
Elizabeth A. Nathan ◽  
Karen Simmer

<b><i>Background:</i></b> Vitamin A has anti-inflammatory and immune-modulating properties. We aimed to assess whether enteral water-soluble vitamin A supplementation in extremely preterm infants decreases fecal calprotectin, a marker of intestinal inflammation. <b><i>Methods:</i></b> This was a prospective observational study nested in a randomized, double-blind, placebo-controlled clinical trial investigating enteral vitamin A (5,000 IU/day) for reducing the severity of bronchopulmonary dysplasia (BPD) in extremely preterm infants. Fecal calprotectin levels were measured using enzyme-linked immunosorbent assay after 28 days of Vitamin A or placebo supplementation. <b><i>Results:</i></b> Fecal calprotectin was measured in 66 infants (Vitamin A: 33, Placebo: 33). The mean (standard deviation) gestational age (25.5 [1.55] vs. 25.8 [1.48]; <i>p</i> = 0.341) (week), birth weight (810 [200] vs. 877 [251]; <i>p</i> = 0.240) (gram), and factors influencing fecal calprotectin levels were comparable between the vitamin A versus placebo group infants. All infants were exclusively fed with mother’s or donor’s human breast milk if mother’s milk was unavailable using a standardized feeding regimen and received prophylactic probiotic supplementation. Fecal calprotectin levels (median; 25th–75th centiles) (micrograms/gram of feces) were not significantly different between vitamin A (152; 97–212) and placebo groups (179; 91–313) (<i>p</i> = 0.195). Two infants in the vitamin A group developed definite necrotizing enterocolitis compared to none in the placebo group. Incidence of BPD at 36 weeks postmenstrual age was similar between the groups (vitamin A: 18/33, placebo: 13/33, <i>p</i> = 0.218). <b><i>Conclusion:</i></b> Enteral supplementation with water-soluble vitamin A did not affect fecal calprotectin levels in extremely preterm infants. Studies with a larger sample size are required to confirm the findings.

2005 ◽  
Vol 146 (6) ◽  
pp. 846-847 ◽  
Author(s):  
Helen Mactier ◽  
Peter Galloway ◽  
Ruth Hamilton ◽  
Lawrence Weaver

2018 ◽  
Vol 23 ◽  
pp. 245-251 ◽  
Author(s):  
Vera Westin ◽  
Susanna Klevebro ◽  
Magnus Domellöf ◽  
Mireille Vanpée ◽  
Boubou Hallberg ◽  
...  

Neonatology ◽  
2017 ◽  
Vol 112 (3) ◽  
pp. 211-216 ◽  
Author(s):  
Ariel A. Salas ◽  
Nazia Kabani ◽  
Colm P. Travers ◽  
Vivien Phillips ◽  
Namasivayam Ambalavanan ◽  
...  

Neonatology ◽  
2020 ◽  
Vol 117 (3) ◽  
pp. 365-368
Author(s):  
Abhijeet A. Rakshasbhuvankar ◽  
Michael W. Clarke ◽  
Karen Simmer ◽  
Sanjay K. Patole ◽  
J. Jane Pillow

<b><i>Background:</i></b> Salivary measurement of hormones and vitamins is gaining prominence as a minimally invasive procedure with the negligible potential for harm. We aimed to assess the utility of saliva for assessing vitamin A status in extremely preterm infants. <b><i>Methods:</i></b> Paired saliva and blood samples were collected at 4 weeks of age from infants born &#x3c;28 weeks of gestation using a proprietary polymer swab. Plasma retinol was measured using high-performance liquid chromatography, and salivary retinol was measured using enzyme-linked immunosorbent assay. <b><i>Results:</i></b> Thirty infants were recruited with a median (IQR) gestation and birth weight of 26.2 weeks (24.8–27.2) and 865 g (718–1,002), respectively. An adequate volume of saliva (&#x3e;50 µL) was obtained in 68%. There was no significant correlation (Spearman’s correlation coefficient = 0.16, <i>p</i> = 0.3) between individual plasma and salivary retinol levels. Bland-Altman analysis showed wide limits of agreement (–113 to +119%) between individual plasma and salivary retinol levels. <b><i>Conclusion:</i></b> Individual vitamin A status cannot be determined reliably from saliva in extremely preterm infants using current collection materials and analysis techniques.


Vaccines ◽  
2021 ◽  
Vol 9 (8) ◽  
pp. 909
Author(s):  
Bettina Bohnhorst ◽  
Cornelia Weidlich ◽  
Corinna Peter ◽  
Carolin Böhne ◽  
Evelyn Kattner ◽  
...  

Due to frequent cardiorespiratory events (CREs) in response to the first routine immunization (rIM), current guidelines recommend readmitting and monitoring extremely preterm infants after the second rIM, though evidence on CREs in response to the second rIM is weak. In a prospective observational study, preterm infants with an increase in CREs after the first rIM were monitored for CREs before and after the second rIM. Seventy-one infants with a median gestational age of 26.4 weeks and a median weight of 820 g at birth were investigated at a median postnatal age of 94 days. All but seven infants showed an increase in CREs after the second rIM. The frequency of hypoxemias (p < 0.0001), apneas (p = 0.0003) and cardiorespiratory events requiring tactile stimulation (CRE-ts) (p = 0.0034) increased significantly. The 25 infants (35%) presenting with CRE-ts were significantly more likely to have been continuously hospitalized since birth (p = 0.001) and to receive analeptic therapy at the first rIM (p = 0.002) or some kind of respiratory support at the first (p = 0.005) and second rIM (p < 0.0001). At a postmenstruational age of 43.5 weeks, CRE-ts ceased. Our data support the recommendation to monitor infants who fulfil the above-mentioned criteria during the second rIM up to a postmenstruational age of 44 weeks.


Sign in / Sign up

Export Citation Format

Share Document